Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways / Yosef Yarden, Moshe Elkabets, editors.
Yarden, Y. (Yosef), editor.; Elkabets, Moshe, editor.
2018
RC271.C5
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways / Yosef Yarden, Moshe Elkabets, editors.
ISBN 9783319679327 (electronic book)
3319679325 (electronic book)
9783319679303
3319679309
DOI https://doi.org/10.1007/978-3-319-67932-7
Published Cham, Switzerland : Springer, 2018.
Language English
Description 1 online resource.
Item Number 10.1007/978-3-319-67932-7 doi
Call Number RC271.C5
Dewey Decimal Classification 616.99/4061
Summary This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Bibliography, etc. Note Includes bibliographical references and index.
Access Note Access limited to authorized users.
Digital File Characteristics text file PDF
Source of Description Online resource; title from PDF title page (SpringerLink, viewed April 5, 2018).
Added Author Yarden, Y. (Yosef), editor.
Elkabets, Moshe, editor.
Series Resistance to targeted anti-cancer therapeutics ; v. 15.
Available in Other Form Print version: 3319679309
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Resistance of colorectal tumors to anti-EGFR antibodies
Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK
Mechanisms of action and resistance of trastuzumab in breast cancer
Mechanisms of resistance to molecular therapies targeting the HGF/MET axis
RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge
Mechanisms of resistance to PI3K and AKT inhibitors
Sensitivity and resistance to BH3 mimetics in cancer therapy
Resistance mechanisms to cyclin-dependent kinase inhibitors
Resistance to inhibitors of angiogenesis.

Browse Subjects

Show more subjects...

Statistics

from
to
Export